FDA grants priority review status to Gilead's hepatitis C drug
June 7 (Reuters) - Biotechnology company Gilead Sciences Inc said the U.S. Food and Drug Administration (FDA) granted priority review to its experimental hepatitis C drug sofosbuvir.
The FDA grants priority reviews to medicines that are considered potentially significant therapeutic advancements over existing therapies.
The FDA set a review date of Dec. 8 for the drug, Gilead said.
Gilead's oral drug is considered the most advanced and high-profile of treatments free of interferon, a standard hepatitis C drug which has side effects including colds and muscle fatigue.
Drugmakers AbbVie and Bristol-Myers Squibb are also developing such treatments but they require patient to take more pills each day than Gilead's treatment.
- Obama unveils U.S. immigration reform, setting up fight with Republicans |
- Officials make preparations for Ferguson grand jury decision |
- More arrests as protesters await Ferguson grand jury decision
- U.S., Iran discussing new ideas to break nuclear impasse: sources
- 'Immoral, but not illegal': metal warehousing games in the spotlight
We are living longer but not creating financial plans to keep pace. Advisers give tips on how to make sure you don’t outlive your money. Video